GlaxoSmithKline's tafenoquine tablets received a positive opinion from the FDA's Antimicrobial Drugs Advisory Committee, thus recommending tafenoquine for approval. The drug was developed as a radical cure and preventive medication for relapse of malaria caused by Plasmodium vivax.
FDA committee backs GlaxoSmithKline's tafenoquine tablets for malaria
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.